Celldex Therapeutics, Inc. (CLDX) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Celldex Therapeutics, Inc. (CLDX) Bundle
Whether you’re an investor or analyst, this (CLDX) DCF Calculator is your go-to resource for accurate valuation. Equipped with real data from Celldex Therapeutics, Inc., you can adjust forecasts and observe the effects in real time.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.6 | 7.4 | 4.7 | 2.4 | 6.9 | 8.8 | 11.3 | 14.6 | 18.7 | 24.0 |
| Revenue Growth, % | 0 | 107.61 | -37.3 | -49.32 | 192.02 | 28.34 | 28.34 | 28.34 | 28.34 | 28.34 |
| EBITDA | -49.7 | -45.6 | -66.1 | -104.2 | -139.0 | -8.8 | -11.3 | -14.6 | -18.7 | -24.0 |
| EBITDA, % | -1390.06 | -615.3 | -1420.77 | -4420.87 | -2019.96 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 4.9 | 2.0 | 3.1 | 1.4 | 3.0 | 5.2 | 6.7 | 8.6 | 11.1 | 14.2 |
| Depreciation, % | 135.96 | 26.96 | 65.96 | 59.4 | 43.7 | 59.21 | 59.21 | 59.21 | 59.21 | 59.21 |
| EBIT | -54.5 | -47.6 | -69.1 | -105.6 | -142.0 | -8.8 | -11.3 | -14.6 | -18.7 | -24.0 |
| EBIT, % | -1526.03 | -642.26 | -1486.73 | -4480.27 | -2063.66 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 64.4 | 194.4 | 408.3 | 305.0 | 423.6 | 8.8 | 11.3 | 14.6 | 18.7 | 24.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.0 | 1.8 | .2 | .3 | 2.6 | 1.9 | 2.5 | 3.2 | 4.1 | 5.2 |
| Account Receivables, % | 28.41 | 24.29 | 3.7 | 14.72 | 38.18 | 21.86 | 21.86 | 21.86 | 21.86 | 21.86 |
| Inventories | -1.0 | -1.8 | -.2 | -.3 | .0 | -1.3 | -1.6 | -2.1 | -2.7 | -3.4 |
| Inventories, % | -28.41 | -24.29 | -3.7 | -14.72 | 0 | -14.22 | -14.22 | -14.22 | -14.22 | -14.22 |
| Accounts Payable | 1.2 | 1.0 | 1.2 | 3.3 | 3.5 | 4.0 | 5.1 | 6.5 | 8.4 | 10.7 |
| Accounts Payable, % | 32.86 | 14.13 | 26.4 | 141.71 | 50.76 | 44.83 | 44.83 | 44.83 | 44.83 | 44.83 |
| Capital Expenditure | -.7 | -1.6 | -1.2 | -1.8 | -1.8 | -3.0 | -3.9 | -5.0 | -6.4 | -8.3 |
| Capital Expenditure, % | -20.46 | -20.92 | -26.85 | -77.56 | -26.41 | -34.44 | -34.44 | -34.44 | -34.44 | -34.44 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -54.0 | -46.7 | -68.9 | -115.4 | -142.0 | -8.8 | -11.3 | -14.5 | -18.6 | -23.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -48.7 | -46.4 | -66.9 | -113.7 | -143.3 | -4.2 | -7.5 | -9.7 | -12.4 | -15.9 |
| WACC, % | 11.96 | 11.96 | 11.96 | 11.96 | 11.96 | 11.96 | 11.96 | 11.96 | 11.96 | 11.96 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -33.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -16 | |||||||||
| Terminal Value | -163 | |||||||||
| Present Terminal Value | -93 | |||||||||
| Enterprise Value | -126 | |||||||||
| Net Debt | -32 | |||||||||
| Equity Value | -94 | |||||||||
| Diluted Shares Outstanding, MM | 48 | |||||||||
| Equity Value Per Share | -1.94 |
What You Will Get
- Real Celldex Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Celldex Therapeutics, Inc. (CLDX).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Celldex.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Celldex’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Celldex Therapeutics, Inc. (CLDX).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility in your analysis of Celldex.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Celldex Therapeutics, Inc. (CLDX).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
- Customizable Forecast Assumptions: Adjust growth projections, capital investments, and discount rates to fit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Celldex Therapeutics, Inc. (CLDX).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for streamlined analysis.
How It Works
- 1. Access the Template: Download and open the Excel file featuring Celldex Therapeutics, Inc. (CLDX) preloaded data.
- 2. Adjust Assumptions: Modify key inputs such as growth rates, WACC, and capital expenditures tailored to Celldex Therapeutics, Inc. (CLDX).
- 3. View Results Instantly: The DCF model automatically calculates the intrinsic value and NPV for Celldex Therapeutics, Inc. (CLDX).
- 4. Explore Scenarios: Analyze various forecasts to evaluate different valuation outcomes for Celldex Therapeutics, Inc. (CLDX).
- 5. Present with Confidence: Share professional valuation insights to bolster your decision-making regarding Celldex Therapeutics, Inc. (CLDX).
Why Choose Celldex Therapeutics, Inc. (CLDX) Calculator?
- All-in-One Solution: Features DCF, WACC, and financial ratio analyses tailored for biotech investments.
- Flexible Inputs: Modify highlighted cells to explore different investment scenarios.
- In-Depth Analysis: Automatically computes Celldex’s intrinsic value and Net Present Value.
- Preloaded Information: Access to historical and projected data for reliable assessments.
- Expert-Level Tool: Perfect for financial analysts, investors, and healthcare consultants.
Who Should Use This Product?
- Biotech Students: Explore drug development processes and apply theoretical knowledge to real-world scenarios.
- Researchers: Integrate advanced models into your studies on immunotherapy and cancer treatments.
- Investors: Evaluate your investment strategies and analyze the market performance of Celldex Therapeutics, Inc. (CLDX).
- Market Analysts: Enhance your analysis with a customizable model tailored for biotech companies.
- Healthcare Entrepreneurs: Understand the valuation methods used for emerging biotech firms like Celldex Therapeutics, Inc. (CLDX).
What the Template Contains
- Pre-Filled DCF Model: Celldex Therapeutics’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Celldex’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.